摘要
目的探讨联合检测血清癌抗原125(CA125)、CA72-4和CA199的含量对卵巢癌的临床诊断价值。方法卵巢癌患者59例,卵巢良性病变49例,及健康妇女50例。用电化学发光免疫测定CA125、CA72-4和CA199含量。结果与良性病变组和健康妇女组相比,卵巢癌患者血清CA125、CA72-4和CA199的含量和阳性率明显升高(P<0.01),三项标志物的阳性检出率分别是79.7%、61.0%和44.8%,CA125和CA72-4联检的阳性率为89.8%,CA125和CA199联检的阳性率为81.3%,三者联合检测阳性率为91.5%。结论联合检测CA125、CA72-4和CA199对卵巢癌的诊断具有重要临床价值。
Objective To study the significance of combined detection of serum levels of CA125 .CA72 -4 and CA199 in diagnosis of ovarian carcinoma. Methods Serum levels of CA125,CA72 -4 and CA199 in 59 patients with ovarian carcinoma, 49 patients with benign ovarian tumor and 50 healthy women for control were measured by Elctrechemilluminescent immunoassay（ECLIA）. Results The serum levels of CA125 ,CA72 -4 and CA199 in patients with ovarian carcinoma group were significantly higher than those in patients with benign ovarian tumor and normal control groups （ P 〈0.01 ）. Their positive rates of CA125,CA72 -4 and CA199 were 79.7% ,61.0% and 44.8% respectively. The sensitivity of combined detection of CA125 and CA72 - 4 was 89.8% , and the sensitivity of combined detection of CA125 and CA199 was 81.3%. The sensitivity of combined detection of three kinds of tumor markers was 91.5%. Conclusion The significance of combined detection of serum levels of CA125 ,CA72 -4 and CA199 is clinically important in the diagnosis of ovarian carcinoma.
出处
《临床和实验医学杂志》
2007年第11期32-33,共2页
Journal of Clinical and Experimental Medicine
